A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Dapagliflozin/gemigliptin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors LG Chem
Most Recent Events
- 22 Jul 2024 New trial record